Ignacio Muñoz-Sanjuan is an expert in neurodevelopment, neural physiology and stem cells, concentrating on the identification and pharmacological modulation of novel pathways for the treatment of neurodegenerative disorders.
He completed his PhD in Molecular Biology and Genetics at the Johns Hopkins University School of Medicine and received a Helen Hay Whitney Foundation Fellowship to investigate the molecular basis of early neural development at Rockefeller University. After this postdoctoral fellowship, he joined Merck Sharp & Dohme in the United Kingdom as a Research Fellow. There, he led a program on the pharmacological modulation of targets critical for adult neural stem cell proliferation and synaptic plasticity that focused on finding new treatments for psychiatric conditions. He then joined Amgen, Inc as a Senior Scientist, where he led several projects in the area of neurodegeneration, with an emphasis on non-amyloid strategies for Alzheimer's disease. He joined CHDI in 2007.
Continuing Medical Education Credit
Continuing Medical Education (CME) credit is being offered for 2019 - 2020 Genetics and Genomics Grand Rounds series through the University of Arizona College of Medicine - Tucson.
The University of Arizona College of Medicine – Tucson is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Arizona College of Medicine – Tucson designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
2019 - 2020 Genetics and Genomics Grand Rounds Learning Objectives
- Integrate advances in genetic diagnosis and treatment into the day-to-day practices of research and clinical care.
- Order appropriate diagnostic evaluations for patients with hereditary medical conditions.
All Faculty, CME Planning Committee Members, and the CME Office Reviewers have disclosed that they do not have any relevant financial relationships with commercial interests that would constitute a conflict of interest concerning this CME activity.